empty
 
 
in
खोज
सहायता
तुरंत खाता खोलना
ट्रेडिंग प्लेटफॉर्म
जमा/ निकासी
खोज
नए लोगों के लिए ट्रेडर्स के लिए पार्टनर्स के लिए एक ब्रेक ले लें About InstaSpot
in
#AZN Return to the list of instruments #BIIB

Currency converter

BeiGene Ltd.
189.29 USD
26 Nov 2024 20:27
Price Change (% chg)
$0
(0%)
Prev Close
Prev Close

Closing price, the previous day.
$189.02
Open
Open

Opening price.
$191.2
Day's High
Day's High

The highest price over the last trading day.
$190.36
Day's Low
Day's Low

The lowest price over the last trading day
$185.22
Week High
Week High

Price range high in the last week
$190.36
Week Low
Week Low

Price range low in the last week
$183.79
Download archive
Buy
189.29
Sell
189.29
Open the chart in full screen view
Buy
189.29
Sell
189.29
Download archive
Open the chart in full screen view

BeiGene Ltd. About company

BeiGene Ltd. is a China-based biotechnology company founded in 2010 in Beijing. Nowadays, the company operates on an international scale with its branches established in the US, Australia, and Europe.

The company focuses on the development of drugs for cancer treatment. Since 2019, BeiGene Ltd. has been in partnership with Amgen Inc. and since, 2021 – with Novartis.

The market capitalization of BeiGene Ltd. is worth $17.7 billion. The company yielded a profit of $1.176 billion last year. In the first half of 2022, it earned $341.57 million. On the flip side, its net losses measured $1.413 billion in 2021 and $571.45 million in the first half of 2022.

BeiGene Ltd.’s stock and what influences its market quotes

BeiGene Ltd.’s stock has traded on the Nasdaq exchange under a BGNE ticker since 2016. Shortly after the listing, the shares traded at $24 apiece.

For the time being, the stock is trading in the range of $138 to $145. The stock has traded between the borders of $121.11 and $389.34 over the last 12 months.

The company does not pay dividends. All funds raised through investments are allocated for research and development.

What factors should investors keep an eye on when trading this asset:

  • BeiGene’s business belongs to a rapidly-developing sector. So, the company should have its finger on the pulse of science not to lag behind its competitors.
  • The major risk is that the company is sensitive to regulatory acts.
  • Washington slaps sanctions on Chinese companies now and then. In this context, they might be delisted from American exchanges.
  • The company ranks high. Hence, its stock is attractive to investors.

अभी बात नहीं कर सकते?
अपना प्रश्न पूछें बातचीत.